Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

580 Articles

Chris Lange | Jun 10, 2016 at 8:05 AM EDT

Major Pharma Has Short Sellers on the Run

The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Lee Jackson | Jun 7, 2016 at 8:25 AM EDT

4 Jefferies Franchise List Dividend Stocks to Buy Now

Moving some capital to lower volatility stocks makes sense as we head into summer. These four Jefferies Franchise Picks look…

Chris Lange | Jun 6, 2016 at 1:40 PM EDT

How Credit Suisse Views Major Pharma After ASCO

The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two…

Chris Lange | Jun 2, 2016 at 10:50 AM EDT

Merrill Lynch Picks ASCO Winners

Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology…

Lee Jackson | May 25, 2016 at 10:05 AM EDT

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue…

Chris Lange | May 25, 2016 at 8:15 AM EDT

Short Sellers Take Mixed Stance on Major Pharma

The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | May 12, 2016 at 7:40 AM EDT

ASCO Could Make or Break These 7 Cancer Drug Trials

The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society…

Chris Lange | May 11, 2016 at 8:45 AM EDT

Major Pharma Short Interest Continues to Recede

The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical…

Trey Thoelcke | May 5, 2016 at 7:35 AM EDT

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an…

Chris Lange | Apr 28, 2016 at 9:10 AM EDT

Why AbbVie Earnings Failed to Impress Investors

AbbVie reported its first-quarter financial results and guidance before the markets opened on Thursday.

Chris Lange | Apr 27, 2016 at 9:15 AM EDT

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Sam Stebbins | Apr 26, 2016 at 6:57 AM EDT

The World’s 15 Top Selling Drugs

Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also…

Lee Jackson | Apr 20, 2016 at 8:25 AM EDT

2 Cheap Pharmaceuticals Highlight Jefferies Franchise Picks Dividend Stocks to Buy

These four Jefferies Franchise Picks are rated Buy and pay the highest dividends. They make good sense for investors now.

Chris Lange | Apr 12, 2016 at 9:50 AM EDT

Short Sellers Become More Selective in Major Pharma

The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Lee Jackson | Apr 4, 2016 at 8:35 AM EDT

4 Jefferies Franchise Picks With Big Dividends Are Solid Q2 Buys

Now all investor eyes turn to first-quarter earnings results. With interest rates still very low, investors looking to add capital…

1 … 28 29 30 31 32 … 39

AbbVie : ABBV

All AbbVie Articles

Major Pharma Has Short Sellers on the Run

4 Jefferies Franchise List Dividend Stocks to Buy Now

How Credit Suisse Views Major Pharma After ASCO

Merrill Lynch Picks ASCO Winners

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

ASCO Could Make or Break These 7 Cancer Drug Trials

Major Pharma Short Interest Continues to Recede

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

Why AbbVie Earnings Failed to Impress Investors

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

The World’s 15 Top Selling Drugs

2 Cheap Pharmaceuticals Highlight Jefferies Franchise Picks Dividend Stocks to Buy

Short Sellers Become More Selective in Major Pharma

4 Jefferies Franchise Picks With Big Dividends Are Solid Q2 Buys

$10,000 in Grayscale’s Ethereum Staking ETF Became $5,328 in Six Months as Ether’s 46% Collapse Erased Staking Income

$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways

58% of Americans Think a 401(k) Balance Is Enough. 48% Have No Plan to Use It.

58% of Americans Think a 401(k) Balance Is Enough. 48% Have No Plan to Use It.

How a 73-Year-Old's First RMD Suddenly Pushed Her Effective Tax Rate to 40 Percent

$10,000 in Grayscale’s Ethereum Staking ETF Became $5,328 in Six Months as Ether’s 46% Collapse Erased Staking Income

$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways

AbbVie : ABBV

All AbbVie Articles

Major Pharma Has Short Sellers on the Run

4 Jefferies Franchise List Dividend Stocks to Buy Now

How Credit Suisse Views Major Pharma After ASCO

Merrill Lynch Picks ASCO Winners

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

ASCO Could Make or Break These 7 Cancer Drug Trials

Major Pharma Short Interest Continues to Recede

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

Why AbbVie Earnings Failed to Impress Investors

Major Pharma Short Interest Remains Mixed, With 1 Massive Drop

The World’s 15 Top Selling Drugs

2 Cheap Pharmaceuticals Highlight Jefferies Franchise Picks Dividend Stocks to Buy

Short Sellers Become More Selective in Major Pharma

4 Jefferies Franchise Picks With Big Dividends Are Solid Q2 Buys

$10,000 in Grayscale’s Ethereum Staking ETF Became $5,328 in Six Months as Ether’s 46% Collapse Erased Staking Income

$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways

58% of Americans Think a 401(k) Balance Is Enough. 48% Have No Plan to Use It.

Featured Reads

58% of Americans Think a 401(k) Balance Is Enough. 48% Have No Plan to Use It.

How a 73-Year-Old's First RMD Suddenly Pushed Her Effective Tax Rate to 40 Percent